نتائج البحث - Yun‐Gyoo Lee

  • يعرض 1 - 10 نتائج من 10
تنقيح النتائج
  1. 1
    Neutrophil‐to‐lymphocyte ratio and risk of lung cancer mortality in a low‐risk population: A cohort study

    Neutrophil‐to‐lymphocyte ratio and risk of lung cancer mortality in a low‐risk population: A cohort study حسب JiHoon Kang, Yoosoo Chang, Jiin Ahn, Sukjoong Oh, Dong‐Hoe Koo, Yun‐Gyoo Lee, Ho Cheol Shin, Seungho Ryu

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report

    Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report حسب James Chih‐Hsin Yang, Frances A. Shepherd, Dong‐Wan Kim, Gyeong‐Won Lee, Jong Seok Lee, Gee‐Chen Chang, Sung Sook Lee, Yu‐Feng Wei, Yun Gyoo Lee, Gianluca Laus, Barbara Collins, Francesca Pisetzky, Leora Horn

    منشور في 2019
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Long‐term outcomes in patients with advanced and/or metastatic non–small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real‐world data (KCSG LU20‐11)

    Long‐term outcomes in patients with advanced and/or metastatic non–small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after... حسب Hong-Sik Kim, Dong‐Wan Kim, Miso Kim, Youngjoo Lee, Hee Kyung Ahn, Jang Ho Cho, Il Hwan Kim, Yun‐Gyoo Lee, Seong Hoon Shin, Song Ee Park, Ji Yoon Jung, Eun Joo Kang, Myung‐Ju Ahn

    منشور في 2021
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Risk factors and prognostic impact of venous thromboembolism in Asian patients with non-small cell lung cancer

    Risk factors and prognostic impact of venous thromboembolism in Asian patients with non-small cell lung cancer حسب Yun‐Gyoo Lee, Eunyoung Lee, Soo‐Mee Bang, Chang Hyun Kang, Young Tae Kim, Hak Jae Kim, Hong‐Gyun Wu, Young Whan Kim, Tae Min Kim, Keun-Wook Lee, Se-Hoon Lee, Dong‐Wan Kim, Dae Seog Heo, Inho Kim

    منشور في 2014
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13–01)

    Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13–01) حسب Yun‐Gyoo Lee, Eun Joo Kang, Bhumsuk Keam, Jin-Hyuk Choi, Jin-Soo Kim, Keon Uk Park, Kyoung Eun Lee, Jung Hye Kwon, Keun‐Wook Lee, Min Kyoung Kim, Hee Kyung Ahn, Seong Hoon Shin, Hye Ryun Kim, Sung‐Bae Kim, Hwan‐Jung Yun

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201

    Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201 حسب Byoung Chul Cho, Ji‐Youn Han, Ki Hyeong Lee, Yun‐Gyoo Lee, Dong‐Wan Kim, Young Joo Min, Sang‐We Kim, Eun Kyung Cho, Joo-Hang Kim, Gyeong‐Won Lee, Sung Sook Lee, NaMi Lee, Jang Young Wang, Hyejoo Park, Myung‐Ju Ahn

    منشور في 2024
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Polypharmacy, Inappropriate Medication Use, and Drug Interactions in Older Korean Patients with Cancer Receiving First-Line Palliative Chemotherapy

    Polypharmacy, Inappropriate Medication Use, and Drug Interactions in Older Korean Patients with Cancer Receiving First-Line Palliative Chemotherapy حسب Soojung Hong, Ju Hyun Lee, Eun Kyeong Chun, Kwang‐Il Kim, Jin Won Kim, Se Hyun Kim, Yun‐Gyoo Lee, In Gyu Hwang, Jin Young Kim, Su-Jin Koh, Yoon Ho Ko, Seong Hoon Shin, In Sook Woo, Tae Yong Kim, Ji Yeon Baek, Hyun Jung Kim, Hyo Jung Kim, Myung Ah Lee, Jung Hye Kwon, Yong Sang Hong, Hun‐Mo Ryoo, Jee Hyun Kim

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis

    Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis حسب Ross A. Soo, Byoung Chul Cho, Joo-Hang Kim, Myung‐Ju Ahn, Ki Hyeong Lee, Anastasia Zimina, Sergey Orlov, Igor Bondarenko, Yun‐Gyoo Lee, Yueh Ni Lim, Sung Sook Lee, Kyung-Hee Lee, Yong Kek Pang, Chin Heng Fong, Jin Hyoung Kang, Chun Sen Lim, Pongwut Danchaivijitr, Saadettin Kılıçkap, James Chih‐Hsin Yang, Çağatay Arslan, Hana Lee, Seong Nam Park, İrfan Çiçin

    منشور في 2023
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With <i>EGFR</i>- or <i>ALK</i>-Rearranged or Translocated Non–Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)

    Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With <i>EGFR</i>- or <i>ALK</i>-Rearranged or Translocated Non–Small-Cell Lung Cancer (ATT... حسب Sehhoon Park, Tae Min Kim, Ji‐Youn Han, Gyeong‐Won Lee, Byoung Yong Shim, Yun‐Gyoo Lee, Sang‐We Kim, Il Hwan Kim, Suee Lee, Yu Jung Kim, Ji Hyun Park, Sang-Gon Park, Ki Hyeong Lee, Eun Joo Kang, Ju Won Kim, Seong Hoon Shin, Chan‐Young Ock, Byung‐Ho Nam, Jaebong Lee, Hyun Ae Jung, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Myung‐Ju Ahn

    منشور في 2023
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors

    A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors حسب Byoung Chul Cho, Ji‐Youn Han, Sang‐We Kim, Ki Hyeong Lee, Eun Kyung Cho, Yun‐Gyoo Lee, Dong‐Wan Kim, Joo-Hang Kim, Gyeong‐Won Lee, Jong-Seok Lee, Byoung Yong Shim, Jin-Soo Kim, Sang Hoon Chun, Sung Sook Lee, Hye Ryun Kim, Min Hee Hong, Jin Seok Ahn, Jong‐Mu Sun, Youngjoo Lee, Dae Ho Lee, Ji Ah Kang, NaMi Lee, Mijung Kwon, Carin R. Espenschied, Arielle Yablonovitch, Myung‐Ju Ahn

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: